Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle
نویسندگان
چکیده
I n the report by Yin et al, 1 the statement that “many clinicians may misinterpret these directions (in paliperidone palmitate product monograph) to mean that these intramuscular sites (deltoid or gluteal) are interchangeable, and thus therapeutically equivalent” is, in our opinion, not correct. We are writing to clarify some statements from the Yin et al article concerning the deltoid versus gluteal intramuscular injection of paliperidone palmitate. The recommended initiation as stated in the product label of paliperidone palmitate 1-month injection is with a dose of 150mgeqon treatmentday1and100mgeq1 week later, both administered in the deltoid muscle. Here, the deltoid and gluteal injection sites are not interchangeable, and from a clinical point of view, it is important to reach therapeutic concentrations quickly when starting a new antipsychotic. However, after the second initiation dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. The injection sites of the maintenance doses can be used interchangeably, but for deltoid injections, the appropriate needle length is based on the patient's weight (1-in 23G needle for patients weighing <90 kg and 1.5-in 22G needle for patients weighing ≥90 kg). For gluteal injection, regardless of patient weight, the use of a 1.5-in 22G needle is recommended. The use of differently sized needles depending on the weight of the patient for injection into the deltoid muscle is recommended to limit the risk of drug administration into the subcutaneous tissues, which would result in a decreased rate of absorption from the intramuscular site of injection. Different distributions of muscle and adipose tissue, as well as difference in blood flow between the deltoid and gluteal sites, may affect the uptake rate of paliperidone into the circulation from the site of injection. At the deltoid site, the likelihood of an injection that is purely intramuscular is higher compared with that at the gluteal injection site. The hypovascularity of subcutaneous adipose tissue compared with
منابع مشابه
Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration.
A 34-year-old white man in whom schizophrenia was diagnosed at the age of 24 years was trialed over the course of illness on risperidone, olanzapine and aripiprazole. Although he responded well to these medications, he experienced relapses secondary to nonadherence. After discussing options to improve compliance and prevent relapse, he agreed to try longacting injectable paliperidone palmitate....
متن کاملPaliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
OBJECTIVE To examine onset of efficacy of two long-acting injectable atypical antipsychotics in markedly-to-severely ill schizophrenia subjects. METHODS This subgroup analysis included 292 subjects with baseline Clinical Global Impressions-Severity scores of markedly ill or worse from a 13-week, randomized, double-dummy noninferiority study (NCT00589914). Subjects received either: 1) paliperi...
متن کاملOnset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
BACKGROUND Paliperidone palmitate is a long-acting injectable atypical antipsychotic for the acute and maintenance treatment of adults with schizophrenia. The recommended initiation dosing regimen is 234 mg on Day 1 and 156 mg on Day 8 via intramuscular (deltoid) injection; followed by 39 to 234 mg once-monthly thereafter (deltoid or gluteal). These post-hoc analyses addressed two commonly enco...
متن کاملOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
BACKGROUND This post hoc analysis (trial registration: ClinicalTrials.gov NCT00590577) assessed onset of efficacy and tolerability of acute treatment with once-monthly paliperidone palmitate (PP), a long-acting atypical antipsychotic initiated by day 1 and day 8 injections, in a markedly to severely ill schizophrenia population. METHODS Subjects entering the 13-week, double-blind trial were r...
متن کاملRandomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
BACKGROUND This 13-week, double-blind study was conducted to confirm the efficacy and safety of paliperidone palmitate (PP), at dosing regimens approved in other countries, in Asian patients with schizophrenia. METHODS Asian patients (aged ≥20 years) diagnosed with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision criteria), and having a Positi...
متن کامل